IRADIMED Corporation reported a significant increase in financial performance for the third quarter of 2025, with total revenue reaching $21.2 million, a 16% rise from $18.3 million in the same period last year. The company's net income also saw an increase, amounting to $5.6 million, or $0.43 per diluted share, compared to $5.0 million, or $0.40 per diluted share, in the prior year. For the nine months ending September 30, 2025, total revenue was $61.1 million, up 13% from $53.9 million in the same period of 2024, driven primarily by strong demand for its MRI-compatible medical devices and related products.
The company experienced notable changes in its operational metrics, with U.S. sales increasing by 19% to $18.1 million for the quarter, while international sales remained stable at approximately $3.1 million. The growth in revenue was largely attributed to increased sales of the MRidium® IV infusion pump systems and disposables, as well as modifications to the sales incentive plan for patient vital signs monitoring systems. The gross profit margin improved slightly to 78% from 77% year-over-year, reflecting effective cost management despite a 14% increase in the cost of revenue.
In terms of strategic developments, IRADIMED received FDA clearance for its next-generation MRidium® 3870 IV infusion pump system in May 2025, which is expected to enhance its market position as the sole provider of non-magnetic MRI infusion pump devices. The company plans to initiate a strategic rollout of this new product in select healthcare facilities in the fourth quarter of 2025, with full commercial distribution anticipated throughout 2026. Additionally, the company completed the construction of a new corporate office and manufacturing facility in Orlando, Florida, which is expected to support its growth initiatives.
Operationally, IRADIMED's workforce included 29 field sales representatives and 4 regional sales directors as of September 30, 2025. The company reported a total of 12,721,156 shares outstanding, reflecting a slight increase from the previous quarter. The company’s cash and cash equivalents rose to $56.5 million, up from $52.2 million at the end of 2024, indicating a solid liquidity position to support ongoing operations and potential future investments.
Looking ahead, IRADIMED anticipates continued revenue growth for the remainder of fiscal year 2025, primarily due to increased sales of its medical devices and related products. However, the company also expects higher operating expenses, driven by increased sales and marketing efforts, regulatory costs, and general administrative expenses. The management remains optimistic about the company's ability to navigate market conditions and capitalize on its innovative product offerings to sustain growth in the competitive healthcare landscape.
About IRADIMED CORP
Iradimed Corporation develops MRI-compatible medical devices, including infusion pumps and vital signs monitors, designed for safe operation within strong magnetic fields. Its products serve hospitals and critical care facilities worldwide, enabling safe, accurate patient monitoring and fluid delivery during MRI procedures. The company’s innovative, non-magnetic technology offers a competitive advantage in the expanding MRI safety market, focusing on patient safety, workflow efficiency, and regulatory compliance.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.